Starpharma (ASX:SPL) has today announced a Development and Option Agreement with AstraZeneca to progress the development (of a Dendrimer Enhanced Product (DEP) version )of an undisclosed AstraZeneca major marketed oncology medicine.
This is the second (DEP) commercial agreement Starpharma has signed with AstraZeneca.
The first agreement was a multiproduct licence which covers novel oncology drug candidates
The agreement was signed during the 2019 ASCO (American Society of Clinical Oncology) meeting in Chicago.
Under this agreement, Starpharma will conduct preclinical testing of the DEP® version of the AstraZeneca oncology product.
Shares in Starpharma (ASX: SPL) are trading 2.3 per cent higher at $1.33.